Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings: 2017-2025

Historic Retained Earnings for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to -$1.3 billion.

  • Crinetics Pharmaceuticals' Retained Earnings fell 49.17% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 49.17%. This contributed to the annual value of -$952.1 million for FY2024, which is 45.65% down from last year.
  • Crinetics Pharmaceuticals' Retained Earnings amounted to -$1.3 billion in Q3 2025, which was down 8.33% from -$1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Retained Earnings' 5-year high stood at -$190.5 million during Q1 2021, with a 5-year trough of -$1.3 billion in Q3 2025.
  • Its 3-year average for Retained Earnings is -$832.4 million, with a median of -$794.7 million in 2024.
  • Data for Crinetics Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 71.39% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Retained Earnings stood at -$275.3 million in 2021, then plummeted by 59.55% to -$439.2 million in 2022, then slumped by 48.85% to -$653.7 million in 2023, then plummeted by 45.65% to -$952.1 million in 2024, then slumped by 49.17% to -$1.3 billion in 2025.
  • Its Retained Earnings stands at -$1.3 billion for Q3 2025, versus -$1.2 billion for Q2 2025 and -$1.0 billion for Q1 2025.